The “Good Manufacturing Practice Zentrum” (GMP-Zentrum; GMP Centre) of Tübingen University Hospital was officially opened on 16th July. The GMP-Zentrum was established to enable the production of individualised vaccines and antibodies according to the rules of good pharmaceutical practice for the treatment of cancer patients.
"Tübingen is the first university in Germany to manufacture newly discovered pharmaceutically active substances in the quality stipulated by pharmacopoeia," said Klaus Tappeser, Head of Department in the Baden-Württemberg Ministry of Science, Research and the Arts. Previously, patients did not have access to newly discovered active substances because they potentially contained traces of other, unwanted, substances.
"The new GMP-Zentrum enables the rapid translation of scientific findings into practice for the benefit of patients. This type of translational research is a particular strength of the University Hospital in Tübingen and we envisage that this will lead to an important breakthrough in the treatment of cancer," said Tappeser going on to add that "the Baden-Württemberg government supported the establishment of the centre with 3.6 million euros. The total investment in the construction and basic equipment of the centre amounted to 5.2 million euros."
Tappeser found that the University of Tübingen is especially suitable for advancing the translational process from preclinical development to production and initial clinical studies both quickly and effectively. The new centre will produce antibodies, vaccines and stem cells for the personalised treatment of patients suffering from cancer.